First-in-human study of ABBV-706, a seizure-related homolog protein 6 (SEZ6)–targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors.
Chandana S, Choudhury N, Dowlati A, Chiang A, Garmezy B, Kim J, Byers L, Ahn M, Kim T, Kim Y, Han J, Bar J, Zha J, Henner W, Robinson R, KOHLHAPP F, Hingorani P, Papadopoulos K. First-in-human study of ABBV-706, a seizure-related homolog protein 6 (SEZ6)–targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors. Journal Of Clinical Oncology 2024, 42: 3001-3001. DOI: 10.1200/jco.2024.42.16_suppl.3001.Peer-Reviewed Original ResearchSmall cell lung cancerAntibody-drug conjugatesDose escalationNeuroendocrine neoplasmsCentral nervous systemRelapsed/refractory small cell lung cancerApproximate dose-proportional increasesHigh-grade CNS tumorsRecommended phase 2 doseModels of small cell lung cancerHigh-grade neuroendocrine neoplasmsFirst-in-human studyCentral nervous system tumorsClinical benefit rateDose-expansion studyMedian prior linesPhase 2 doseDose-limiting toxicityMaximum tolerated doseDose-proportional increaseCell lung cancerHigh-grade gliomasElimination half-lifeBayesian optimal interval designData cutoff